COLOTTA, VITTORIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.353
EU - Europa 5.558
AS - Asia 1.633
AF - Africa 66
Continente sconosciuto - Info sul continente non disponibili 6
SA - Sud America 5
OC - Oceania 3
Totale 15.624
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.332
RU - Federazione Russa 1.878
IE - Irlanda 826
SE - Svezia 726
IT - Italia 650
PL - Polonia 449
VN - Vietnam 401
SG - Singapore 372
UA - Ucraina 307
HK - Hong Kong 278
CN - Cina 263
DE - Germania 249
FI - Finlandia 173
IN - India 170
GB - Regno Unito 146
JO - Giordania 79
FR - Francia 43
ES - Italia 34
CI - Costa d'Avorio 33
TR - Turchia 26
NL - Olanda 24
SC - Seychelles 24
CH - Svizzera 22
CA - Canada 20
KR - Corea 14
BE - Belgio 9
AT - Austria 7
TH - Thailandia 7
EE - Estonia 6
EU - Europa 6
IL - Israele 5
JP - Giappone 4
NA - Namibia 4
IR - Iran 3
NZ - Nuova Zelanda 3
SA - Arabia Saudita 3
BR - Brasile 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
PK - Pakistan 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AR - Argentina 1
BO - Bolivia 1
CR - Costa Rica 1
CY - Cipro 1
EG - Egitto 1
GE - Georgia 1
ID - Indonesia 1
IS - Islanda 1
KG - Kirghizistan 1
LT - Lituania 1
LV - Lettonia 1
MA - Marocco 1
ME - Montenegro 1
MU - Mauritius 1
PE - Perù 1
UZ - Uzbekistan 1
Totale 15.624
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.729
Fairfield 845
Dublin 825
Chandler 647
Ashburn 570
Jacksonville 457
Warsaw 447
Cambridge 404
Dong Ket 398
Seattle 392
Woodbridge 373
Wilmington 340
Singapore 300
Houston 285
Princeton 181
Ann Arbor 158
Mumbai 151
Boston 137
Hong Kong 129
Altamura 127
Florence 121
Beijing 117
Lawrence 106
Boardman 83
Shanghai 74
Medford 72
Moscow 57
Kent 51
San Diego 46
Buffalo 40
West Jordan 40
Abidjan 33
New York 32
Helsinki 28
Norwalk 27
Milan 24
Barcelona 22
Philadelphia 22
Bern 20
Munich 18
Auburn Hills 17
Falls Church 17
Hillsboro 17
Los Angeles 17
Toronto 16
Washington 16
Ferrara 14
Izmir 14
Rome 14
Frankfurt Am Main 13
Yubileyny 13
Andover 11
Camerino 11
Gavirate 10
Romola 10
Brussels 9
Dearborn 9
Salerno 9
Verona 9
Bremen 8
Padova 8
Lappeenranta 7
London 7
Parma 7
Vienna 7
Cagliari 6
Laurel 6
Pune 6
Tallinn 6
Bury St Edmunds 5
Catania 5
Cavarzere 5
Dalmine 5
Düsseldorf 5
Groningen 5
Guangzhou 5
Jinan 5
Mataró 5
Phoenix 5
Redwood City 5
Shenzhen 5
Venice 5
Amsterdam 4
Grevenbroich 4
Mountain View 4
Pontassieve 4
Tel Aviv 4
Treviso 4
Windhoek 4
Auckland 3
Dallas 3
Frankfurt am Main 3
Grottammare 3
Hefei 3
Nanjing 3
Palermo 3
Panzano in Chianti 3
Puducherry 3
Salt Lake City 3
San Francisco 3
Totale 10.368
Salva come PNG Salva come JPEG
Nome #
Adenosine A2B receptors stimulation inhibits oligodendrocyte maturation by interacting with sphingosine kinase/sphingosine 1-phosphate signalling axis in primary purified oligodendrocyte cultures 244
The identification of the 2-phenylphthalazin-1(2H)-one scaffold as a new decorable core skeleton for the design of potent and selective human A3 adenosine receptor antagonists. 241
1,2,4-Triazolo[4,3-a]quinoxalin-1-one: a versatile tool for the synthesis of potent and selective adenosine receptor antagonists. 205
The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype 201
Synthesis and biological evaluation of novel 9-heteroaryl substituted 7-chloro-4,5-dihydro-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates (TQX) as AMPA receptor antagonists. 196
The 1,2,4-Triazolo[4,3-a]quinoxalin-1-one Moiety as an Attractive Scaffold to Develop New Potent and Selective Human A3 Adenosine Receptor Antagonists: Synthesis, Pharmacological and Ligand-Receptor Modeling Studies. 194
1,2,4-Benzothiadiazine-1,1-dioxide Derivatives as Ionotropic Glutamate Receptor Ligands: Synthesis and Structure–Activity Relationships 175
1,3-DIARYLPYRAZOLO[4,5-C]- AND -[5,4-C]QUINOLIN-4-ONES. 4. SYNTHESIS AND SPECIFIC INHIBITION OF BENZODIAZEPINE RECEPTOR BINDING. 173
“1,2,4-TRIAZOLO[1,5-A]QUINOXALINE DERIVATIVES: SYNTHESIS AND BIOLOGICAL EVALUATION AS ADENOSINE RECEPTOR ANTAGONISTS” 171
1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives. 162
The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A1 and A2A receptor affinity and selectivity profiles 149
1,2,4-Triazolo[4,3-a]pyrazin-3-one as a new scaffold to develop potent adenosine receptor antagonists 142
Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A3 and A2A subtypes 139
1,2,4-triazolo[4,3-a]quinoxalin-1-one as a framework to obtain potent and selective A1, A2A and A3 adenosine receptor antagonists 134
2-Arylpyrazolo[4,3-d]pyrimidin-7-amino Derivatives As New Potent and Selective Human A3Adenosine Receptor Antagonists. Molecular Modeling Studies and Pharmacological Evaluation 133
2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a New Scaffold to obtain Potent and Selective Human A3 Adenosine Receptor Antagonists: New Insights into the Receptor-Antagonist Recognition† 133
1-Substituted pyrazolo[1,5-c]quinazolines as novel Gly/NMDA receptor antagonists: synthesis, biological evaluation and molecular modeling study 132
Functional characterization of a novel adenosine A2B receptor agonist on short-term plasticity and synaptic inhibition during oxygen and glucose deprivation in the rat CA1 hippocampus 127
3-Hydroxy-1H-quinazoline-2,4-dione as a New Scaffold to Develop Potent and Selective Inhibitors of the Tumor-Associated Carbonic Anhydrases IX and XII 127
Synthesis and biological evaluation of a new set of pyrazolo[1,5-c]quinazolines as glycine/N-methyl-D-aspartic acid receptor antagonists 126
A comprehensive strategy in the development of a cyclodextrin-modified microemulsion electrokinetic chromatographic method for the assay of diclofenac and its impurities: Mixture-process variable experiments and quality by design 126
SYNTHESIS, BINDING STUDIES, AND STRUCTURE ACTIVITY RELATIONSHIPS OF 1-ARYL- AND 2-ARYL[1]BENZOPYRANOPYRAZOL-4-ONES, CENTRAL BENZODIAZEPINE RECEPTOR LIGANDS. 125
Modifications on the Amino-3,5-dicyanopyridine Core To Obtain Multifaceted Adenosine Receptor Ligands with Antineuropathic Activity 124
Inhibition of A2Aadenosine receptor signaling in cancer cells proliferation by the novel antagonist TP455 124
Adenosine A2B receptors inhibit K+ currents and cell differentiation in cultured oligodendrocyte precursor cells and modulate sphingosine-1-phosphate signaling pathway 123
Antioxidant-Conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain 121
4,5-Dihydro-1,2,4-triazolo[1,5-a]quinoxalin-4-ones. Excitatory amino acid antagonists with combined glycine/NMDA and AMPA receptor affinity 121
Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand. 119
4-Amino-6-benzylamino-1,2-dihydro-2-phenyl-1,2,4-triazolo[4,3-a] quinoxalin-1-one: a new A2A adenosine receptor antagonist with high selectivity versus A1 receptors. 119
3-Hydroxy-1H-quinazoline-2,4-dione derivatives as new antagonists at ionotropic glutamate receptors: Molecular modeling and pharmacological studies. 119
“3-Hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists” 117
Development of novel pyridazinone-based adenosine receptor ligands 117
Synthesis and biological evaluation of analogues of 7-chloro-4,5-dihydro-4-oxo-8-(1,2,4-triazol-4-yl)-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylic acid (TQX-173) as novel selective AMPA receptor antagonists 116
Structural Investigation of the 7-Chloro-3-hydroxy-1H-quinazoline-2,4-dione Scaffold to Obtain AMPA and Kainate Receptor Selective Antagonists. Synthesis, Pharmacological and Molecular Modeling Studies 116
Synthesis and biological evaluation of a new set of pyrazolo[1,5-c]quinazoline-2-carboxylates as novel excitatory amino acid antagonists 116
7-Chloro-4,5-dihydro-8-(1,2,4-triazol-4-yl)-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates as novel highly selective AMPA receptor antagonists. 115
Structure-activity relationship studies of novel pyrazolo[1,5-c][1,3]benzoxazines: synthesis and benzodiazepine receptor affinity. 115
SYNTHESIS OF 1,5-DIARYL-3-METHYL-1H-PYRAZOLO[4,5-C]ISOQUINOLINES AND STUDIES OF BINDING TO SPECIFIC PERIPHERAL BENZODIAZEPINE BINDING SITES. 115
Structural investigations on coumarins leading to chromeno[4,3-c]pyrazol-4-ones and pyrano[4,3-c]pyrazol-4-ones: New scaffolds for the design of the tumor-associated carbonic anhydrase isoforms IX and XII 115
Design, synthesis, and pharmacological characterization of 2‑(2- furanyl)thiazolo[5,4‑d]pyrimidine-5,7-diamine derivatives: new highly potent A2A adenosine receptor inverse agonists with antinociceptive activity 114
1-(3-Aminophenyl)-3-methyl[1]benzopyrano[2,3-c]pyrazol-4-one: a new selective A2 adenosine receptor antagonist. 114
SYNTHESIS AND BINDING STUDY OF PYRAZOLO[4,5-C][1,8]NAPHTHYRIDINES. 113
SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS OF 4-CYCLOALKYLAMINO-1,2,4-TRIAZOLO[4,3-A]QUINOXALIN-1-ONE DERIVATIVES AS A1 AND A3 ADENOSINE RECEPTOR ANTAGONISTS. 113
Novel AMPA and kainate receptor antagonists containing the pyrazolo[1,5-c]quinazoline ring system: synthesis and structure-activity relationships 111
Tricyclic heteroaromatic systems. Synthesis and benzodiazepine receptor affinity of 2-substituted-1-benzopyrano[3,4-d]oxazol-4-ones, -thiazol-4-ones, and –imidazol-4-ones. 110
Synthesis, glycine/NMDA and AMPA binding activity of some new 2,5,6-trioxopyrazino[1,2,3-de]quinoxalines and of their restricted analogs 2,5-dioxo- and 4,5-dioxoimidazo[1,5,4-de]quinoxalines. 109
TRICYCLIC HETEROAROMATIC SYSTEMS. 5H-1,2,3-TRIAZOLO[5,1-C][1,4]BENZODIAZEPINE. 109
2-Aryl-8-chloro-1,2,4-triazolo[1,5-a]quinoxalin-4-amines as highly potent A1 and A3 adenosine receptor antagonists 109
Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a New Scaffold To Develop Potent and Selective Human A3 Adenosine Receptor Antagonists. Synthesis, Pharmacological Evaluation, and Ligand-Receptor Modeling Studies. 109
TRICYCLIC HETEROCYCLIC SYSTEMS: PYRAZOLO[5',4':4,5]- AND PYRAZOLO[3',4':4,5]PYRANO[2,3-B]PYRIDINE DERIVATIVES. 108
SYNTHESIS OF SOME 2-ARYL-1,2,4-TRIAZOLO[1,5-C][1,3]BENZOXAZIN-5-ONES AS TOOLS TO DEFINE THE ESSENTIAL PHARMACOPHORIC DESCRIPTORS OF A BENZODIAZEPINE RECEPTOR LIGAND. 107
SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS OF 1-AMINOPHTHALAZINIUM SALTS AS GABAA RECEPTOR ANTAGONISTS. 107
TRICYCLIC HETEROAROMATIC SYSTEMS. SYNTHESIS AND A1 AND A2A ADENOSINE BINDING ACTIVITIES OF SOME 1-ARYL-1,4-DIHYDRO-3-METHYL[1]BENZOPYRANO[2,3-C]PYRAZOL-4-ONES, 1-ARYL-4,9-DIHYDRO-3-METHYL-1H-PYRAZOLO[3,4-B]QUINOLIN-4-ONES, AND 1-ARYL-1H-IMIDAZO[4,5-B]QUINOXALINES. 107
7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: Structural investigations at the 5-position to target human A1 and A2A adenosine receptors. Molecular modeling and pharmacological studies 105
TRICYCLIC HETEROAROMATIC SYSTEMS. 5H-1,2,4-TRIAZOLO[5,1-C][1,4]BENZODIAZEPINE. 104
New 2-Arylpyrazolo[3,4-c]quinoline Derivatives as Potent and Selective Human A3 Adenosine Receptor Antagonists. Synthesis, Pharmacological Evaluation and Ligand-Receptor Modeling Studies. 104
Synthesis and Pharmacological Studies at the Gly/NMDA, AMPA and Kainate Receptors of New Oxazolo[4,5-c]quinolin-4-one derivatives bearing different substituents at position-2 and on the fused benzo ring 104
Pyrazoloquinazoline tricyclic system as novel scaffold to design new kinase CK2 inhibitors. 103
Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors 102
1,2,4-Triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A3 receptor antagonists. Synthesis, structure–affinity relationships and molecular modeling studies 102
4-Amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as New Potent and Selective Human A3 Adenosine Receptor Antagonists. Synthesis, Pharmacological Evaluation and Ligand-Receptor Modeling Studies. 102
Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity 102
3-Hydroxy-1H-quinazoline-2,4-dione derivatives as new antagonists at ionotropic glutamate receptors: molecular modeling and pharmacological studies 102
STRUCTURE-ACTIVITY RELATIONSHIPS OF 1,2,4-TRIAZOLO[1,5-A]QUINOXALINES AND THEIR 1-DEAZA ANALOGS IMIDAZO[1,2-A]QUINOXALINES AT THE BENZODIAZEPINE RECEPTOR. 101
TRICYCLIC HETEROAROMATIC SYSTEMS. 1,2,4-TRIAZOLO[1,5-A]QUINOXALINE. 101
Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists. 101
Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A 1 and A 2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells 101
Competitive AMPA receptor antagonists. 100
Competitive Gly/NMDA receptor antagonists 99
Synthesis, structure-affinity relationships, and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists. 99
Nuovi tiazoli[5,4-d]pirimidin derivati quali agonisti inversi dei recettori A2A dell'adenosina 99
New 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives. Evaluation of different moieties on the 6-aryl ring to obtain potent and selective human A2A adenosine receptor antagonists 99
Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation 97
Scouting Human A3 Adenosine Receptor Antagonist Binding Mode Using a Molecular Simplification Approach: From Triazoloquinoxaline to a Pyrimidine Skeleton as a Key Study 97
Tandem 3D-QSARs Approach as a Valuable Tool To Predict Binding Affinity Data: Design of New Gly/NMDA Receptor Antagonists as a Key Study. 96
THE CORRECT SYNTHESIS OF 2,3-DIHYDRO-2-ARYL-4-R-[1]BENZOPYRANO[4,3-C]PYRAZOLE-3-ONES. 96
Synthesis of some tricyclic heteroaromatic systems and their A1 and A2a adenosine binding activity. 95
Acylsilane-mediated nucleophilic acylation of alfa,beta-unsaturated carbonyl derivatives 94
Novel potent and highly selective human A3 adenosine receptor antagonists belonging to the 4-amido-2-arylpyrazolo[3,4-c]quinoline series: molecular docking analysis and pharmacological studies 94
Benzodiazepine binding activity of some tricyclic heteroarometic systems to define the hydrogen bonding strength of the proton donors of the receptor site. 93
Discovery of first-in-class multi-target adenosine A2A receptor antagonists-carbonic anhydrase IX and XII inhibitors. 8-Amino-6-aryl-2-phenyl-1,2,4-triazolo [4,3-a]pyrazin-3-one derivatives as new potential antitumor agents 93
NOVEL ADENOSINE RECEPTOR LIGANDS: 1,3-DISUBSTITUTED[1]BENZOPYRANO[2,3-C]PYRAZOL-4-ONES. SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS. 92
Pharmacological characterization of some selected 4,5-dihydro-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates and 3-hydroxyquinazoline-2,4-diones as (S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionic acid receptor antagonists. 92
TRICYCLIC HETEROAROMATIC SYSTEMS: [1]BENZOPYRANOPYRAZOL-4-ONES AS BENZODIAZEPINE RECEPTOR LIGANDS. 91
Tricyclic heteroaromatic systems. Pyrazolo[3,4-c]quinolin-4-ones and pyrazolo[3,4-c]quinoline-1,4-diones: synthesis and benzodiazepine receptor activity. 91
The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2Breceptor 91
TRICYCLIC HETEROAROMATIC SYSTEMS. [1]BENZOPYRANOPYRROL-4-ONES AND [1]BENZOPYRANO-1,2,3-TRIAZOL-4-ONES AS BENZODIAZEPINE RECEPTOR LIGANDS. SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS. 91
Tricyclic heteroaromatic systems. 1,2,4-triazolo[4,3-a]quinoxalines and 1,2,4-triazino[4,3-a]quinoxalines: synthesis and central benzodiazepine receptor activity. 91
null 90
TRICYCLIC HETEROAROMATIC SYSTEMS: SYNTHESIS, [3H]FLUNITRAZEPAM BRAIN MEMBRANE BINDING INHIBITION, AND STRUCTURE-ACTIVITY RELATIONSHIPS OF 2,3-DIHYDRO-2-ARYL-4-R-[1]BENZOPYRANO[4,3-C]PYRAZOL-3-ONES. 89
2-Aryl-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as new potent adenosine human A2A receptor antagonists 89
Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists: Synthesis, structure–affinity relationships and molecular modeling studies 88
Synthesis and Structure-Activity Relationships of a new set of 2-arylpyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists. 88
Synthesis of 4-amino-6-(hetero)arylalkylamino-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent A2A adenosine receptor antagonists. 88
TRICYCLIC HETEROAROMATIC SYSTEMS. 1,2,3,4-TETRAHYDROPYRAZOLO[4,3-C][1]BENZAZEPIN-1-ONES AS POTENTIAL ANTITUMOR AGENTS. 87
Synthesis and structure-activity relationships of a new set of 1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as adenosine receptor antagonists. 87
REACTION OF 1-AMINOPHTHALAZINES WITH A-HALOCARBONYL COMPOUNDS: IMIDAZO-2,1-A]PHTHALAZINES AND THEIR BENZODIAZEPINE RECEPTOR ACTIVITIES. 85
Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptor 84
CK1 delta inhibition: an emerging strategy to combat neurodegenerative diseases 83
G protein-coupled receptors as potential drug target: from receptor topology to rational drug design, an in silico approach 83
Totale 11.572
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.870
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.870
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.517 0 0 0 0 204 258 208 267 188 143 198 51
2020/20211.824 117 89 131 140 48 184 42 130 126 211 92 514
2021/20221.081 53 124 70 56 34 39 37 72 45 52 186 313
2022/20232.832 270 431 139 189 229 524 414 169 305 16 95 51
2023/20241.323 56 117 191 55 54 329 57 197 38 100 74 55
2024/20254.779 251 843 464 1.043 2.178 0 0 0 0 0 0 0
Totale 15.822